A Science & Innovation Webinar, presented by Mesoblast.

Join us for an insightful webinar on the advancements in treating pediatric steroid-refractory acute versus host disease (SR-aGVHD) with RYONCIL®, which was approved by the FDA on December 19, 2024. We will delve into the significant unmet need in SR-aGVHD, a condition with high morbidity and mortality rates, and how Ryoncil’s safety and efficacy offers a promising new therapeutic option that has significant impact on long-term survival outcomes. We will also explore the potential to deliver significant healthcare cost savings due to substantial long-term survival benefits, utilizing health economic models for ultra-rare diseases and high-impact therapies.

An AMCP Market Insights Webinar.

Join us for a webinar on ER+/HER2- Metastatic Breast Cancer, a disease affecting nearly 150,000 people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care. This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in February 2025. Presenters will characterize the clinical and QOL burden of ER+/HER2, explore the mechanisms of action of current therapies, review current treatment options, describe therapeutics that targets ERs, and outline payer strategies to facilitate precision oncology care.

In this hour-long webinar, health care attorney Ross Margulies of Manatt, Phelps & Phillips, LLP will review the scope of the April 15^th drug pricing executive order and its impact across various health care stakeholders. We will dive into the background and history of the proposals, many of which are being resurfaced from the first Trump Administration, and talk through the pathway and prospects for these policy proposals.

You get a GLP-1! You get a GLP-1! Everyone gets a GLP-1! This encore presentation of the keynote session at AMCP 2025 delves into the transformative potential of GLP-1 receptor agonists (GLP-1RAs) across a wide range of conditions, including obstructive sleep apnea, binge eating disorder, substance use disorder, NASH, heart failure, osteoarthritis, cystic fibrosis, PCOS, and neurocognitive disorders like Parkinson's and Alzheimer's dementia. Attendees will gain insights into the latest advancements in the GLP-1RA pipeline and explore emerging therapies and their potential to reshape treatment paradigms.

Additionally, this discussion will address key implications for managed care and highlight the challenges in formulary management and benefit design. Join us for an in-depth exploration of these innovative therapies and their potential to revolutionize care across diverse health conditions